Specialty R&D
Our innovations meet important medical needs
Our Specialty portfolio delivers innovative medicines focused on meeting important medical needs across therapeutic categories, including neurology (Parkinson’s Disease, Migraine), endocrinology (Hypothyroidism), and other therapeutic areas.
We are focused on the continued growth and expansion of our product portfolio through internal development as well as through acquisitions and late-stage and next-generation product partnership opportunities.
Clinical Activities(1)
Product
Indication
Estimated Launch
CREXONT®
Parkinson’s Disease
Launched Sept. 2024
Pyridostigmine Bromide ER
Pretreatment for soman nerve gas for the U.S. Government
Approved Oct. 2024
DHE Autoinjector
Migraine and Cluster Headache
Q2 2025
Note: Data as of November 8, 2024
(1) Pipeline includes investigational products not approved by FDA. Any such expected launch is subject to certain assumptions and factors, many of which are outside our control, such as regulatory approval, and may be subject to change.
© 2024 Amneal Pharmaceuticals LLC. All rights reserved.